Famciclovir Tablets 250mg (Famciclovir)

Adult dose

1. Treatment of herpes zoster infection Adults: Administer famciclovir 250mg per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this drug 250mg per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this drug 125mg per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this drug 250mg per dose orally twice daily. Temporarily discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Because creatinine clearance of this drug is reduced in patients with renal impairment, adjust the dose with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose twice daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 125 mg per dose twice daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose twice daily 10～29 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formulas. Men: {weight (kg) × (140-age)} / {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment receiving hemodialysis For patients receiving hemodialysis, it is preferable to administer the drug every 48 hours, taking the dialysis interval into consideration. Four hours of hemodialysis reduces the plasma concentration of this drug by approximately 75%; therefore, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with obvious chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be used by patients who are allergic to this medication, its ingredients, or its active ingredient, penciclovir. Additionally, this medication contains lactose, so patients with a genetic disease that prevents lactose digestion should not take it. Patients with impaired kidney function should use this medication with caution. Symptoms such as headache or nausea may occur when taking this medication, but they are typically mild or moderate. In rare cases, blood-related issues such as a decrease in platelet count and a reduction in white blood cells or neutrophils may occur. Common central nervous system effects include headache, dizziness, drowsiness, confusion, and, rarely, hallucination symptoms. Infrequently, symptoms of rapid heart rate have been reported. Common gastrointestinal side effects include nausea, vomiting, abdominal pain, and diarrhea. Liver function test abnormalities are common, and jaundice may occur rarely. Common skin reactions include rash or itching, while urticaria and rare angioedema around the face or eyes may occur. Severe skin reactions or serious adverse effects such as vasculitis have been reported very rarely. In patients with poor kidney function, acute renal failure may rarely occur, necessitating careful dose adjustments based on kidney status. This medication does not completely cure genital herpes; therefore, it is important to avoid sexual intercourse if symptoms are present during treatment to maintain safe sexual practices. If dizziness, drowsiness, or confusion occurs while taking this medication, it is advisable to refrain from driving or operating machinery. Patients with slightly impaired liver function do not require specific dose adjustments; however, patients with severe liver disease may experience diminished efficacy. This medication has minimal major drug interactions, but caution is advised as drug concentrations may change when taken with certain other medications. The safety of this medication during pregnancy is uncertain, and pregnant women should consult a physician and only take it if absolutely necessary. Women who are breastfeeding should also exercise caution when taking this medication, as it may be transmitted through breast milk, and should consult a physician. Children under 18 years should ideally not use this medication since its safety and efficacy have not been established. Generally, elderly patients do not require dose adjustments, but adjustments may be necessary if kidney function is impaired. In case of overdose, appropriate treatment should be administered, and hemodialysis can reduce the concentration of the active ingredient in this medication. This medication should be stored in a dry place below 30 degrees Celsius and kept out of reach of children. Care should be taken as transferring to another container may alter the quality of the product.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucination
• palpitations

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it should be kept in a dry place below 30 degrees Celsius to maintain its effectiveness.

Appearance

White round film-coated tablet

Package unit

21 tablets/box [7 tablets/PTP x 3]